Author: ["Yuichi Oike","Masaki Akao","Kunio Yasunaga","Toshimasa Yamauchi","Tohru Morisada","Yasuhiro Ito","Takashi Urano","Yoshishige Kimura","Yoshiaki Kubota","Hiromitsu Maekawa","Takeshi Miyamoto","Keishi Miyata","Shun-ichiro Matsumoto","Juro Sakai","Naomi Nakagata","Motohiro Takeya","Haruhiko Koseki","Yoshihiro Ogawa","Takashi Kadowaki","Toshio Suda"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Angiopoietin-related growth factor (AGF), a member of the angiopoietin-like protein (Angptl) family, is secreted predominantly from the liver into the systemic circulation. Here, we show that most (>80%) of the AGF-deficient mice die at about embryonic day 13, whereas the surviving AGF-deficient mice develop marked obesity, lipid accumulation in skeletal muscle and liver, and insulin resistance accompanied by reduced energy expenditure relative to controls. In parallel, mice with targeted activation of AGF show leanness and increased insulin sensitivity resulting from increased energy expenditure. They are also protected from high-fat diet–induced obesity, insulin resistance and nonadipose tissue steatosis. Hepatic overexpression of AGF by adenoviral transduction, which leads to an approximately 2.5-fold increase in serum AGF concentrations, results in a significant (P < 0.01) body weight loss and increases insulin sensitivity in mice fed a high-fat diet. This study establishes AGF as a new hepatocyte-derived circulating factor that counteracts obesity and related insulin resistance.Cite this article
Oike, Y., Akao, M., Yasunaga, K. et al. Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nat Med 11, 400–408 (2005). https://doi.org/10.1038/nm1214 